Tests of an experimental drug called CPSI-1306 at Ohio State University were so successful at lowering inflammation and blood sugar levels in lab mice with type 2 diabetes that scientists consider it a prime candidate to become a new therapy for the disease.
Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan (Diovan) delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.
According to Duke University researchers, a mutation that causes the lack of an insulin-controlling molecule may be a factor in the development of type 2 diabetes. The molecule, ankyrin B, is activated in response to the smell and taste of food and leads to the production of insulin in preparation for food intake.
A scientist's discovery that dolphins have a genetic ability to turn diabetes on and off, depending on the availability of food, could lead to research into whether humans might have a similar-although dormant-gene.
The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone) that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug. In addition, the report cherry-picks information from documents, which mischaracterizes GlaxoSmithKline's comprehensive efforts to research Avandia and communicate those findings to regulators, physicians and patients. In fact, the safety and effectiveness of Avandia is well characterized in the label approved by the FDA.
A U.S. Senate Finance Committee report released on February 20 says that Avandia, GlaxoSmithKline's drug for type 2 diabetes, may have caused as many as 83,000 heart attacks between 1999, when the drug was introduced, and 2007. The Senate report, culminating a two-year inquiry into the drug, also says that Glaxo knew about the drug's potential risks years before suspicions began to form regarding a connection between Avandia and heart problems.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.